Hunan Xiangzhong Pharmaceutical Co., Ltd.

Primary objective: To compare the differences in the extent and rate of absorption of lithium carbonate tablets (specification: 0.25 g) provided by Hunan Xiangzhong Pharmaceutical Co., Ltd. and lithium carbonate tablets (trade name: TERALITHE®; specification: 0.25 g) approved by LABORATOIRES DELBERT in healthy Chinese population under fasting and fed conditions. Secondary objective: To evaluate the safety of lithium carbonate tablets (specification: 0.25 g) provided by Hunan Xiangzhong Pharmaceutical Co., Ltd. and lithium carbonate tablets (trade name: TERALITHE®; specification: 0.25 g) approved by LABORATOIRES DELBERT in healthy Chinese population under fasting and fed conditions.

Main research purpose: According to the regulations on bioequivalence testing, select Bripipiprazole Tablets (trade name: REXULTI®, specification: 2 mg) of Otsuka Manufacturing Co., Ltd. as the licensee as the reference preparation. The test preparation Bripiprazole tablets (specification: 2 mg) provided by Xiangzhong Pharmaceutical Co., Ltd. were subjected to fasting and postprandial administration human bioequivalence tests to compare the absorption speed and extent of the drug in the test preparation with the reference preparation. Whether the difference is within the acceptable range, the bioequivalence of the two formulations under fasting and postprandial administration conditions was evaluated. Secondary research purpose: To observe the safety of the test preparation Bripipiprazole Tablets (specification: 2 mg) and the reference preparation Bripipiprazole Tablets (trade name: REXULTI®, specification: 2 mg) orally administered to healthy volunteer subjects.

Main purpose: Using oxcarbazepine tablets provided by Hunan Xiangzhong Pharmaceutical Co., Ltd. as the test preparation, according to the relevant provisions of the bioequivalence test, the absorption rate and degree of oxcarbazepine tablets (trade name: Trileptin®, reference preparation) produced by Novartis Farma S.p.A. were compared in healthy humans, and the human bioequivalence of the two preparations was investigated. Secondary purpose: To observe the safety of the test preparation oxcarbazepine tablets and the reference preparation oxcarbazepine tablets (trade name: Trileptin®) in healthy subjects.